Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Equity ETF median (66 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 21 Nov 2018 – 20 Aug 2026, limited by Mirae Asset Nifty 50 ETF. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | Mirae Asset Nifty 50 ETF | Nifty 50 |
|---|---|---|
| 21 Nov 2018 | ₹100.00 | ₹100.00 |
| 15 Jul 2019 | ₹110.05 | ₹109.32 |
| 07 Mar 2020 | ₹105.38 | ₹103.67 |
| 28 Oct 2020 | ₹112.92 | ₹110.66 |
| 21 Jun 2021 | ₹152.61 | ₹148.55 |
| 12 Feb 2022 | ₹169.34 | ₹163.91 |
| 06 Oct 2022 | ₹170.67 | ₹163.51 |
| 29 May 2023 | ₹183.98 | ₹175.46 |
| 20 Jan 2024 | ₹214.98 | ₹203.98 |
| 12 Sep 2024 | ₹255.29 | ₹239.52 |
| 06 May 2025 | ₹246.10 | ₹230.00 |
| 27 Dec 2025 | ₹265.38 | ₹245.68 |
| 20 Aug 2026 | ₹249.12 | ₹228.60 |
| Metric | Mirae Asset NAV ₹263.81 Very High risk ★★★★☆ | Category median Equity ETF · 66 funds |
|---|---|---|
| -2.26% | +3.95% | |
| +9.05% | +11.55% | |
| +9.28% | +10.41% | |
| — | +11.81% | |
| +12.51% | +8.19% | |
| +7.64% | — | |
| +15.64% | +13.71% | |
| +15.97% | +14.22% | |
| — | +12.98% | |
| Risk | ||
| 13.24% | 17.16% | |
| 0.19 | 0.22 | |
| 0.27 | 0.32 | |
| -38.29% | -20.98% | |
| Nifty 50 | — | |
| +1.11% | +0.65% | |
| 1.00 | 1.00 | |
| 102.7% | 101.0% | |
| 96.2% | 97.0% | |
| 0.07% | 0.37% | |
| ₹5,184Cr | ₹91.02Cr | |
| — | — | |
| — | — | |
| — | — | |
| — | — | |
| — | — | |
| — | — | |
| 21 Nov 2018 | — | |
| 50 | — | |
| 52.7% | — | |
| — | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.